梅萨实验室
MLAB
122.48
-5.26
-4.12%
梅萨实验室
US · MLAB
#3485 按市值排名
122.48
-5.26
-4.12%
实时 - 追踪5344个代码 - 心跳于203秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了1.3个百分点。
机构持股
- 机构持股比例
- 90.74% -1.35pp
- 机构数量
- 206 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund64.84%
Hedge Fund18.41%
Public Company4.63%
Individual/Insider3.10%
Private Company1.75%
Government Pension Fund0.71%
Family Office/Trust0.21%
Insurance Company0.19%
Other6.16%
主要股东 截至 2026-06-30
Long Path Partners, LP
8.53% · 477.13K 股
BlackRock
7.87% · 440.55K 股
Vanguard Capital Management, LLC
4.95% · 276.99K 股
Boston Partners Global Investors, Inc.
4.74% · 265.15K 股
AQR Capital Management
3.61% · 202.10K 股
Ranger Investment Management, L.P.
3.11% · 173.99K 股
Diamond Hill Capital Management, LLC
2.78% · 155.77K 股
Raymond James Financial, Inc.
2.68% · 149.94K 股
Dimensional Fund Advisors
2.65% · 148.40K 股
Geode Capital Management, LLC
2.50% · 139.68K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 27次买入 · 13次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| John Sullivan | Chairperson | 1.17% |
| John Sakys | VP, CFO & Chief Accounting Officer | 0.67% |
| Brian Archbold | Senior Vice President of Continuous Improvement | 0.33% |
| Shiraz Ladiwala | Lead Independent Director | 0.22% |
| R. Tripeny | Independent Director | 0.16% |
| Jennifer Alltoft | Independent Director | 0.14% |
| Siddhartha Kadia | Chief Executive Officer | 0.13% |
| Shannon Hall | Independent Director | 0.12% |
| Mark Capone | Director | 0.11% |
| Lyndsey Crennen | Chief Accounting Officer | 0.04% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-08 | Shiraz Ladiwala | Lead Independent Director | Other Derivative Acquisition | +2,510 | -- |
| 2026-09-08 | John Sullivan | Chairperson | Other Derivative Acquisition | +1,774 | -- |
| 2026-09-08 | R. Tripeny | Independent Director | Other Derivative Acquisition | +1,774 | -- |
| 2026-09-08 | Mark Capone | Director | Other Derivative Acquisition | +2,423 | -- |
| 2026-09-08 | Shannon Hall | Independent Director | Other Derivative Acquisition | +1,774 | -- |
| 2026-08-26 | Gary Owens | Chief Executive Officer | Intent to Sell (Form 144) | -20,358 | $127.75 |
| 2026-08-20 | Gary Owens | Chief Executive Officer | Intent to Sell (Form 144) | -20,000 | $122.50 |
| 2026-08-14 | Shiraz Ladiwala | Lead Independent Director | Derivative Exercise and Retained | +3,810 | -- |
| 2026-08-14 | John Sullivan | Chairperson | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | R. Tripeny | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Mark Capone | Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Shannon Hall | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Jennifer Alltoft | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-12 | John Sullivan | Chairperson | Private Disposition | -7,093 | $112.80 |
| 2026-08-12 | R. Tripeny | Independent Director | Open Market Acquisition | +900 | $113.69 |
| 2026-08-12 | Siddhartha Kadia | Chief Executive Officer | Private Acquisition | +7,093 | $112.80 |
| 2026-06-21 | John Sakys | VP, CFO & Chief Accounting Officer | Automatic Disposition | -2,827 | $89.50 |
| 2026-06-21 | Brian Archbold | Senior Vice President of Continuous Improvement | Open Market Disposition | -2,516 | $89.50 |
| 2026-06-21 | Lyndsey Crennen | Chief Accounting Officer | Automatic Disposition | -442 | $89.50 |
| 2026-06-17 | John Sakys | VP, CFO & Chief Accounting Officer | Other Acquisition | +2,282 | $95.10 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
梅萨实验室 讨论区 0 条评论